Treatments:
In total, 66 (70.6%) of 93 hospitalized CAP patients received
intravenous sulbactam ampicillin (SAM). Of these patients, 24 (25.8%)
were treated with simultaneous peroral macrolide. Further, of 18 CCAP
patients, 16 (88.8%) received intravenous vancomycin and cefotaxime; 6
(33.3%), clindamycin; and 3 (16.66%), peroral macrolide. Three
(3.22%) CAP patients underwent CT scan in addition to thoracic USG due
to fever lasting >3 days and clinical deterioration. Then,
treatment was modified in CCAP patients. The initial treatment protocols
significantly differed between the two groups (p<0.001)
(Table-4).